Differences in Responses to Neoadjuvant Anti-HER2 Therapy between HER2 2+/ISH+ and HER2 3+ in HER2-Positive Breast Cancer. - Ma, Lingjun; Zheng, Ran; Xu, Lingyun; Zhu, Ying; Yin, Hong; Zhang, Xiaoqing; Deng, Rong; Wang, Jue; Zha, Xiaoming (Cancer Research & Treatment, 2026)